Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)

China flag China · Delayed Price · Currency is CNY
26.62
+0.25 (0.95%)
Jan 23, 2026, 3:04 PM CST
Market Cap6.04B
Revenue (ttm)1.14B
Net Income (ttm)228.68M
Shares Out226.80M
EPS (ttm)1.01
PE Ratio26.40
Forward PE22.37
Dividend0.20 (0.76%)
Ex-Dividend DateJul 17, 2025
Volume1,356,962
Average Volume969,338
Open25.92
Previous Close26.37
Day's Range25.92 - 26.63
52-Week Range25.03 - 33.56
Beta0.27
RSI56.41
Earnings DateApr 27, 2026

About SHE:002880

Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 198... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1985
Employees 859
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002880
Full Company Profile

Financial Performance

In 2024, SHE:002880's revenue was 1.20 billion, an increase of 14.75% compared to the previous year's 1.05 billion. Earnings were 253.52 million, an increase of 15.95%.

Financial Statements